Indication name: Alagille
Syndrome (ALGS)
Alagille syndrome (ALGS) – Market
outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019
To 2030
Alagille syndrome is caused by
mutations in one of two genes – the JAG1 gene or the NOTCH2 gene. Mutations of
the JAG1 gene have been identified in more than 88 percent of cases. Mutations
in the NOTCH2 gene account for less than 1 percent of cases.
Competitive landscape of ALGS
includes country specific approved as well as pipeline therapies. Any asset/
product specific designation or review and Accelerated Approval are being
tracked and supplemented with analyst commentary.
Thelansis Epidemiology study
indicates incidnece of ALGS is approximately 1 in 30,000-45,000 individuals in
the general population.
KOLs insights of ALGS across 8 MM
market from center of Excellence/ Public/ Private hospitals participated in the
study. Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm and Unmet needs.
ALGS Market Forecast: Patient
Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs
with sourcing , Market Event and Product Event , Country specific Forecast
Model, Market uptake and patient share uptake , Attribute Analysis , Analog
Analysis , Disease burden and pricing scenario, Summary and Insights.
S. No Asset Company Partner Stage
1 Maralixibat Mirum Pharmaceuticals, Inc. Lumena Pharmaceuticals, Inc. Phase 2
2 Odevixibat Albireo Phase 3
No comments:
Post a Comment